Horizon Therapeutics

Execution time: 0.0007 seconds

Execution time: 0.0006 seconds

Execution time: 0.0005 seconds

On January 21, 2020, the U.S. Food and Drug Administration (FDA) approved TEPEZZA® (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED) – making it the first and only approved medicine to treat this serious, progressive and vision-threatening rare autoimmune disease. Historically, patients impacted by TED had no approved options for medical treatment and had to suffer in pain until the inflammation subsided – which could take years – risking severe and permanent damage to their eyes. With TEPEZZA, patients living with TED now have a treatment that treats the cause of the disease and not just the symptoms. TEPEZZA is one of the most successful rare disease medicine launches in history – a direct result of the immense unmet need that previously pervaded the TED community. Even more impressive is the fact that this success was achieved amidst the backdrop of the COVID-19 pandemic. TEPEZZA launched just six weeks before a major COVID-19 outbreak in the U.S.